ISN-ACT Clinical Trial List: December 2018
ISN Academy. ISN-ACT . Dec 13, 2018; 234815
Topic: General Nephrology
Disclosure(s): The ISN-Advancing Clinical Trials is a new initiative of the ISN intended to leverage existing infrastructures within ISN, in order to improve global nephrology community participation in clinical trial research. As part of its activities, the ISN-ACT highlights and sometimes analyzes important recent nephrology trials from latest medical literature every month through the ISN-ACT Trial-list. Editors of the ISN-ACT Trial-List also select clinical trials of particular impact, and collaborate with the @ISNeducation social media learning team to represent these trials visually. Join the ISN-ACT To generate more high-quality clinical trials and studies in nephrology, ISN-ACT is calling on investigators and interested individuals. If you are an ISN member interested to join this great initiative, submit your application online. Use the button below (download PDF) to download this month's edition of the list.
Login now to access Regular content available to all registered users.

You may also access ISN content "anytime, anywhere" with the FREE ISN Academy App for iOS and Android.
Discussion Forum (0)
Rate & Comment (0)
Once a month, the ISN-ACT (Advancing Clinical Trials) team collects and publishes a list of important nephrology trials from the latest medical literature. Each trial is reviewed in context and their risk of bias in seven key areas assessed. This month, we reviewed the following trials: - Tyrosine kinase inhibition shows promise in diabetic nephropathy JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial Tuttle, et al. Nephrol Dial Transplant. 2018;33(11):1950-1959 - Despite lowering HbA1c, linagliptin provides no benefit in patients with T2DM and CKD Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial Rosenstock, et al. JAMA. 2018 Nov 9. doi: 10.1001/jama.2018.18269 - Intensive immunosuppression improves short-term remission rates in lupus nephritis Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study An, et al. Clin Rheumatol. 2018 Nov 28. doi: 10.1007/s10067-018-4368-8 ​ - New calcimimetic on the block demonstrates efficacy Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism Fukagawa, et al. Kidney Int. 2018;94(4):818-825 - Topiroxostat may reduce albuminuria in chronic kidney disease Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial Mizukoshi, et al. Nephrology. 2018;23(11):1023-1030 A preview of this infographic is available below, and can be downloaded to the left.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings